EPIX Stock Forecast 2025-2026
Distance to EPIX Price Targets
EPIX Price Momentum
🤔 Considering Essa Pharma (EPIX)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Latest EPIX Stock Price Targets & Analyst Predictions
Based on our analysis of 6 Wall Street analysts, EPIX has a neutral consensus with a median price target of $1.99 (ranging from $1.65 to $30.97). Currently trading at $1.62, the median forecast implies a 22.9% upside. This outlook is supported by 0 Buy, 4 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
EPIX Analyst Ratings
EPIX Price Target Range
Latest EPIX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for EPIX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 4, 2024 | Piper Sandler | Joseph Catanzaro | Neutral | Downgrade | $2.00 |
| Nov 4, 2024 | Oppenheimer | Leland Gershell | Perform | Downgrade | $0.00 |
| Nov 1, 2024 | Jones Trading | Soumit Roy | Hold | Downgrade | $0.00 |
| May 16, 2024 | Oppenheimer | Leland Gershell | Outperform | Maintains | $17.00 |
| Dec 13, 2023 | Oppenheimer | Mark Breidenbach | Outperform | Reiterates | $17.00 |
| Aug 9, 2023 | Oppenheimer | Mark Breidenbach | Outperform | Reiterates | $17.00 |
| Jun 26, 2023 | Oppenheimer | Mark Breidenbach | Outperform | Assumes | $17.00 |
| May 12, 2022 | Piper Sandler | Joseph Catanzaro | Overweight | Maintains | $20.00 |
| Aug 17, 2021 | Oppenheimer | Mark Breidenbach | Outperform | Maintains | $22.00 |
| Mar 4, 2021 | Piper Sandler | Overweight | Initiates | $0.00 | |
| Feb 25, 2021 | HC Wainwright & Co. | Joseph Pantginis | Buy | Maintains | $32.00 |
| Feb 11, 2021 | HC Wainwright & Co. | Joseph Pantginis | Buy | Maintains | $36.00 |
| Jan 11, 2021 | HC Wainwright & Co. | Buy | Maintains | $17.00 | |
| Oct 25, 2019 | Oppenheimer | Outperform | Initiates | $0.00 | |
| Mar 26, 2018 | HC Wainwright & Co. | Buy | Initiates | $0.00 | |
| Mar 26, 2018 | H.C. Wainwright | Buy | Initiates | $0.00 |
Essa Pharma Inc. (EPIX) Competitors
The following stocks are similar to Essa Pharma based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Essa Pharma Inc. (EPIX) Financial Data
Essa Pharma Inc. has a market capitalization of $71.47M with a P/E ratio of -2.5x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -24.0%.
Valuation Metrics
Growth & Margins
Financial Health
🔥 Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
Essa Pharma Inc. (EPIX) Business Model
About Essa Pharma Inc.
Develops therapies for prostate cancer treatment.
Essa Pharma Inc. operates by developing small molecule therapies that target the N-terminal domain of the androgen receptor, which is crucial for prostate cancer treatment. The company generates value through its proprietary compounds that aim to provide new treatment options for patients, particularly those resistant to existing therapies, by advancing its clinical candidates through trials.
Headquartered in Vancouver, Canada, Essa Pharma is active in the pharmaceutical and biotechnology sectors, focusing on oncology. The company engages in collaborations and research partnerships to address unmet medical needs and enhance cancer therapeutics.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
35
CEO
Dr. David Ross Parkinson M.D.
Country
Canada
IPO Year
2015
Website
www.essapharma.comEssa Pharma Inc. (EPIX) Latest News & Analysis
Levi & Korsinsky, LLP has announced a class action securities lawsuit against ESSA Pharma Inc. (NASDAQ: EPIX), alerting investors to potential legal implications.
The class action lawsuit against ESSA Pharma Inc. could impact the company's stock price and investor confidence, reflecting potential legal risks and financial liabilities.
A class action lawsuit has been filed against ESSA Pharma Inc. (NASDAQ: EPIX) for securities violations. Investors from December 12, 2023, to October 31, 2024, should contact Schall Law Firm by March 25, 2025.
A class action lawsuit against ESSA Pharma for securities violations may indicate potential financial risks, impacting share prices and investor confidence during the class period.
Investors in ESSA Pharma Inc. (NASDAQ:EPIX) who experienced losses may explore potential recovery options under federal securities laws. More details available via the provided link.
The mention of a potential lawsuit against ESSA Pharma Inc. signals legal issues that could impact the company's stock performance and investor confidence.
A class action lawsuit has been filed against ESSA Pharma Inc. and certain officers for alleged securities law violations, affecting investors who purchased shares between Dec 12, 2023, and Oct 31, 2024.
The class action lawsuit against ESSA Pharma raises concerns about potential legal liabilities and regulatory violations, which could negatively impact the company's stock performance and investor confidence.
Investors in ESSA Pharma Inc. (NASDAQ:EPIX) who experienced losses may explore potential recovery options under federal securities laws. More information can be found through the provided link.
The news indicates potential legal action regarding ESSA Pharma, which may affect stock price and investor sentiment, signaling risk for current and prospective shareholders.
Investors in ESSA Pharma Inc. (NASDAQ:EPIX) who incurred losses may explore recovery options under federal securities laws. For details, visit the provided link or contact an attorney.
Legal actions can signal financial instability or mismanagement in a company, potentially affecting stock prices and investor confidence in ESSA Pharma.
Frequently Asked Questions About EPIX Stock
What is Essa Pharma Inc.'s (EPIX) stock forecast for 2025?
Based on our analysis of 6 Wall Street analysts, Essa Pharma Inc. (EPIX) has a median price target of $1.99. The highest price target is $30.97 and the lowest is $1.65.
Is EPIX stock a good investment in 2025?
According to current analyst ratings, EPIX has 0 Buy ratings, 4 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.62. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for EPIX stock?
Wall Street analysts predict EPIX stock could reach $1.99 in the next 12 months. This represents a 22.9% increase from the current price of $1.62. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Essa Pharma Inc.'s business model?
Essa Pharma Inc. operates by developing small molecule therapies that target the N-terminal domain of the androgen receptor, which is crucial for prostate cancer treatment. The company generates value through its proprietary compounds that aim to provide new treatment options for patients, particularly those resistant to existing therapies, by advancing its clinical candidates through trials.
What is the highest forecasted price for EPIX Essa Pharma Inc.?
The highest price target for EPIX is $30.97 from at , which represents a 1,811.9% increase from the current price of $1.62.
What is the lowest forecasted price for EPIX Essa Pharma Inc.?
The lowest price target for EPIX is $1.65 from at , which represents a 1.7% increase from the current price of $1.62.
What is the overall EPIX consensus from analysts for Essa Pharma Inc.?
The overall analyst consensus for EPIX is neutral. Out of 6 Wall Street analysts, 0 rate it as Buy, 4 as Hold, and 0 as Sell, with a median price target of $1.99.
How accurate are EPIX stock price projections?
Stock price projections, including those for Essa Pharma Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
